Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nang Kuang Pharmaceutical CoTPE:1752 -0.63%88 ROC (Joel Greenblatt) % is 12.06% as of Dec. 2025, which is 5% above its 10-year median of 11.46. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.68 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 837 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 59.62% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Nang Kuang Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.06%.
The historical rank and industry rank for Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TPE:1752'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.52 Med: 11.46 Max: 20.25
Current: 11.98
During the past 13 years, Nang Kuang Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 20.25%. The lowest was 5.52%. And the median was 11.46%.
TPE:1752's ROC (Joel Greenblatt) % is ranked better than 59.62% of 837
companies
in the Medical Devices & Instruments industry
Industry Median: 4.35
vs TPE:1752: 11.98
Nang Kuang Pharmaceutical Co (TPE:1752) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co ROC (Joel Greenblatt) % Chart
TPE:1752 vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Nang Kuang Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.06% mean?
Nang Kuang Pharmaceutical Co (TPE:1752) has a ROC (Joel Greenblatt) % of 12.06% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Nang Kuang Pharmaceutical Co and its competitors. This is near median its historical median of 11.46. Over the past decade, Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 5.52 to 20.25. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #338 out of 837 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Nang Kuang Pharmaceutical Co's current ROC (Joel Greenblatt) % of 12.06% is near median its 10-year median of 11.46. Over the past 10 years, this metric has ranged from a low of 5.52 to a high of 20.25. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.35. Nang Kuang Pharmaceutical Co's value of 12.06% is 177.2% above this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #338 out of 837 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #338 out of 837 companies for ROC (Joel Greenblatt) %. This puts Nang Kuang Pharmaceutical Co in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 4.35. Nang Kuang Pharmaceutical Co's value of 12.06% is 177.2% above this benchmark. Historically, Nang Kuang Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 5.52 to 20.25 over the past decade. While the company's 10-year median is 11.46 vs. the industry median of 4.35, Nang Kuang Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.35, based on 837 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current ROC (Joel Greenblatt) % of 12.06% is 177.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Nang Kuang Pharmaceutical Co and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current ROC (Joel Greenblatt) % is 12.06%, which is near median its own 10-year median of 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.68, compared to a current price of NT$31.60 — trading 32.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.06%, which is near median its 10-year median of 11.46 and 177.2% above the Medical Devices & Instruments industry median of 4.35. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current ROC (Joel Greenblatt) % is 12.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.60 is trading 32.3% below its estimated GF Value™ of NT$46.68.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TPE:1752:
ROC (Joel Greenblatt) %: 12.06% (near median its 10-year median of 11.46)
GF Value™: NT$46.68 vs. price of NT$31.60 (32.3% below fair value)
Industry Position: 177.2% above the Medical Devices & Instruments median (#338 of 837)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score
Get the complete analysis for TPE:1752
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
